Skip to main content
. 2016 Aug 18;26:16049. doi: 10.1038/npjpcrm.2016.49

Table 3. Severity and clinical management of asthma population prescribed 1–9 ICS+COMBI per year, by number of SABA inhalers (N=20,884).

  Total N (%) 1–3 N (%) 4–12 N (%) 13+N (%)
  20,884 9,451 (45.3) 10,285 (49.3) 1,148 (5.5)
         
Clinical measures
 Asthma review 19,787 (94.8) 8,739 (92.5) 9,919 (96.4) 1,129 (98.3)
 Asthma management plan 17,471 (83.7) 7,603 (80.5) 8,848 (86.0) 1,020 (88.9)
 Asthma step recorded 18,498 (88.6) 7,986 (84.5) 9,435 (91.7) 1,077 (93.8)
         
Asthma severitya
 Step 1 3,060 (16.5) 1,621 (20.3) 1,313 (13.9) 126 (11.7)
 Step 2 11,929 (64.5) 5,279 (66.1) 6,085 (64.5) 565 (52.5)
 Step 3 3,153 (17.1) 1,023 (12.8) 1,831 (19.4) 299 (27.8)
 Step 4/5 356 (1.9) 63 (0.8) 206 (2.2) 87 (8.1)
         
Healthcare resource use
 Count IP episodes 447 122 239 86
 Crude IP episode, rate per 100 population 2.14 1.29 2.32 7.49

Abbreviations: COMBI, combination inhalers (ICS and Long-acting β2-agonist); ICS, inhaled corticosteroid; IP, inpatient; SABA, short-acting β2-agonist.

a

Asthma step % as a proportion of total with asthma step recorded.